Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jun 24, 2021 10:23am
127 Views
Post# 33441013

RE:RE:RE:RE:RE:RE:Every time Mugsy Posts

RE:RE:RE:RE:RE:RE:Every time Mugsy Posts
MikeStock wrote:
MrMugsy wrote: Yes - a paid promoter.
Made a couple million as a professional promoter.

Is this the caliber of investor we're getting over here now ?

: )


I’ve wondered the same thing before about Mugs, but at the end of the day, what does it matter if he is or isn’t. Did he tell any of you to buy or did he tell any of you to sell?  The answer is clearly no. He shares an opinion, and it’s typically positive but then there’s others that share things that are always negative. Are those people paid too? Again, what does it matter.

ATE management needs to do a better job at building some excitement about this stock and the potential of the drug pipeline. What happens here is just a blip and won’t move the needle.

We’re expecting a corporate update before end of month. We’ve got one new analyst covering us. We need a positive update and we need more analysts and we need more institutions buying. These 100 share buys are a joke and so are the people selling into the bid.

Many of us are holding bags at the moment (myself included) and it’s not fun but it’s the nature of the beast, so we wait, or we sell and take a loss. We can each decide that. In the meantime, ignore someone if you don’t like what they say. GLTA and let’s hope this update in the coming days is a good one.  



Thanks Mike.

But make no mistake - if someone was willing to pay me to be here, I'd likely take it.
I just don't know where to find that Sugar Daddy ... hahaha !
<< Previous
Bullboard Posts
Next >>